2010
Rethinking Prevention of HIV Type 1 Infection
Burns DN, Dieffenbach CW, Vermund SH. Rethinking Prevention of HIV Type 1 Infection. Clinical Infectious Diseases 2010, 51: 725-731. PMID: 20707698, PMCID: PMC3071685, DOI: 10.1086/655889.Peer-Reviewed Original ResearchEstimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: a hard hit area along a major drug trafficking route
Duan S, Shen S, Bulterys M, Jia Y, Yang Y, Xiang L, Tian F, Lu L, Xiao Y, Wang M, Jia M, Jiang H, Vermund SH, Jiang Y. Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: a hard hit area along a major drug trafficking route. BMC Public Health 2010, 10: 180. PMID: 20374618, PMCID: PMC2858119, DOI: 10.1186/1471-2458-10-180.Peer-Reviewed Original ResearchConceptsHIV incidenceDiscordant couplesHIV epidemicMajor drug trafficking routesRecent HIV-1 infectionAnnual HIV incidenceHIV-discordant couplesHIV-1 prevalenceHIV-1 incidenceHIV-1 infectionMigration of HIVFemale sex workersPre-marital couplesCross-sectional surveyBED IgGRecent seroconversionIntensive prevention measuresHIV-positivePregnant womenHIV preventionHigh riskResultsFrom 2004Drug usersMultivariate analysisEnzyme immunoassay
2009
Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges
Wester CW, Bussmann H, Koethe J, Moffat C, Vermund S, Essex M, Marlink RG. Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Therapy 2009, 3: 501-526. PMID: 20161344, PMCID: PMC2774911, DOI: 10.2217/hiv.09.35.Peer-Reviewed Original ResearchCombination antiretroviral therapyAntiretroviral therapyUse of cARTFirst-line combination antiretroviral therapyHIV-1-infected adultsPrimary HIV-1 infectionMonths of treatmentHIV-1 infectionResource-rich settingsHigh mortality rateImmunologic recoveryVirologic suppressionHIV infectionHealthcare utilizationSaharan AfricaAdherence ratesLifelong monitoringPROGRESS trialTreatment outcomesMortality rateCART programClinical servicesImpressive declineTherapyInfection
2003
CC Chemokine Receptor 5 Genotype and Susceptibility to Transmission of Human Immunodeficiency Virus Type 1 in Women
Philpott S, Weiser B, Tarwater P, Vermund SH, Kleeberger CA, Gange SJ, Anastos K, Cohen M, Greenblatt RM, Kovacs A, Minkoff H, Young MA, Miotti P, Dupuis M, Chen CH, Burger H. CC Chemokine Receptor 5 Genotype and Susceptibility to Transmission of Human Immunodeficiency Virus Type 1 in Women. The Journal Of Infectious Diseases 2003, 187: 569-575. PMID: 12599073, PMCID: PMC3319124, DOI: 10.1086/367995.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Virus type 1HIV-1-seronegative womenHIV-1-seropositive womenDelta 32Women's Interagency HIV StudyType 1CC chemokine receptor 5HIV-1 transmissionHIV-1 infectionChemokine receptor 5Differential genetic susceptibilityHeterosexual spreadHIV StudyHIV-1Receptor 5Male cohortGenetic susceptibilityPartial protectionWomenBehavioral factorsInfectionHeterozygous genotypeMost studies
2002
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents
Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH, Kaslow RA. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002, 16: 2275-2284. PMID: 12441799, DOI: 10.1097/00002030-200211220-00007.Peer-Reviewed Original ResearchConceptsViral loadHLA class IHost genetic profileHIV-1-infected adolescentsHIV-1-seropositive participantsCD4 T-cell countClass IHIV-seronegative individualsT-cell countsCD4 T lymphocytesHIV-1 infectionHIV-1 pathogenesisGenetic profileClinical patient groupsAntiretroviral therapyQuarterly followMultivariable analysisHealth cohortPatient groupImmunological outcomesImmunological controlNegative HLAT lymphocytesProtective effectAdolescent careHIV-1 and HIV-2 Seroprevalence and Risk Factors Among Hospital Outpatients in the Eastern Region of Ghana, West Africa.
Chang LW, Osei-Kwasi M, Boakye D, Aidoo S, Hagy A, Curran JW, Vermund SH. HIV-1 and HIV-2 Seroprevalence and Risk Factors Among Hospital Outpatients in the Eastern Region of Ghana, West Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2002, 29: 511. PMID: 11981368, DOI: 10.1097/00042560-200204150-00012.Peer-Reviewed Original ResearchConceptsHIV seroprevalence ratesSeroprevalence ratesRisk factorsHIV-1HIV-2 seroprevalenceHIV-1 infectionHigh-risk populationCross-sectional studyHIV infectionHIV statusHIV-2Hospital outpatientsMultivariable modelPrenatal patientsDual infectionRisk populationsAnonymous studyInfectionRecord dataIntervention programsOutpatientsPatientsUrbanized communitiesSeroprevalenceHospitalHIV-1 and HIV-2 Seroprevalence and Risk Factors Among Hospital Outpatients in the Eastern Region of Ghana, West Africa
Chang L, OseiKwasi M, Boakye D, Aidoo S, Hagy A, Curran J, Vermund S. HIV-1 and HIV-2 Seroprevalence and Risk Factors Among Hospital Outpatients in the Eastern Region of Ghana, West Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2002, 29: 511-516. DOI: 10.1097/00126334-200204150-00012.Peer-Reviewed Original ResearchHIV seroprevalence ratesSeroprevalence ratesRisk factorsHIV-1HIV-2 seroprevalenceHIV-1 infectionHigh-risk populationCross-sectional studyHIV infectionHIV statusHIV-2Hospital outpatientsMultivariable modelPrenatal patientsDual infectionRisk populationsAnonymous studyInfectionRecord dataIntervention programsOutpatientsPatientsUrbanized communitiesSeroprevalenceHospital
1999
Rapid Communication CCR5 Genotype and Resistance to Vertical Transmission of HIV-1
Philpott S, Burger H, Charbonneau T, Grimson R, Vermund S, Visosky A, Nachman S, Kovacs A, Tropper P, Frey H, Weiser B. Rapid Communication CCR5 Genotype and Resistance to Vertical Transmission of HIV-1. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 21: 189-193. PMID: 10421241, DOI: 10.1097/00126334-199907010-00002.Peer-Reviewed Original ResearchConceptsHIV-1 infectionHIV-1Vertical transmissionCCR5 genotypeHIV-1 infection statusHIV-1 vertical transmissionHIV-1-infected mothersPrimary HIV-1 infectionMacrophage-tropic strainsAfrican AmericansParenteral transmissionUninfected childrenChild transmissionInfected childrenInfected mothersInfected womenDelta32 mutationCCR5 receptorInfection statusWhite childrenCCR5MothersChildrenHomozygous genotypeAdditional strategies
1998
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection
1992
The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Graham N, Zeger S, Park L, Vermund S, Detels R, Rinaldo C, Phair J. The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 326: 1037-1042. PMID: 1347907, DOI: 10.1056/nejm199204163261601.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSPneumocystis carinii pneumoniaPCP prophylaxisProlong survivalEarly treatmentRelative riskVirus infectionCell countUse of zidovudineUse of prophylaxisDiagnosis of AIDSHIV Type 1HIV-1 infectionBasis of CD4High-risk menInitial disease stateProbability of deathZidovudine usersZidovudine therapyImmunodeficiency syndromeCarinii pneumoniaClinical symptomsProphylaxis
1991
Estimating the 1978–1990 and Future Spread of Human Immunodeficiency Virus Type 1 in Subgroups of Homosexual Men
Hoover D, Munoz A, Carey V, Chmiel J, Taylor J, Margolick J, Kingsley L, Vermund S. Estimating the 1978–1990 and Future Spread of Human Immunodeficiency Virus Type 1 in Subgroups of Homosexual Men. American Journal Of Epidemiology 1991, 134: 1190-1205. PMID: 1746529, DOI: 10.1093/oxfordjournals.aje.a116022.Peer-Reviewed Original ResearchConceptsSeroconversion ratesHomosexual menHuman immunodeficiency virus type 1 (HIV-1) infectionHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Kaplan-Meier methodHIV-1 infectionType 1 infectionAge 55 yearsHIV-1 epidemicVirus type 1AIDS diagnosisSeroconversionAnnual hazardHematologic variablesAge 55Type 1Survival methodsBisexual menHomosexual populationCohortMenAgeInfectionEffect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
STUDY T, Graham N, Zeger S, Park L, Saah A, Phair J, Detels R, Vermund S, Ho M. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Lancet 1991, 338: 265-269. PMID: 1677108, DOI: 10.1016/0140-6736(91)90414-k.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAerosolsCD4-Positive T-LymphocytesEvaluation Studies as TopicFollow-Up StudiesHIV SeropositivityHIV-1HumansLeukocyte CountMalePentamidinePneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsTime FactorsTrimethoprim, Sulfamethoxazole Drug CombinationZidovudineConceptsPneumocystis carinii pneumoniaEffect of zidovudineHIV-1 infectionPCP prophylaxisProbability of progressionLymphocytes/First episodePneumocystis carinii pneumonia prophylaxisHIV-1-infected individualsHIV-1-seropositive menMonth intervalsPrimary PCP prophylaxisEfficacy of zidovudinePresence of HIVRate of progressionMultivariate log-linear modelPneumonia prophylaxisMore CD4Primary prophylaxisZidovudine therapyLymphocyte countCarinii pneumoniaClinical trialsObservational studyProphylaxis